Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131-I-TM-601 in Adult Patients With Recurrent High-Grade Glioma

NCT00114309 is registered in ClinicalTrials.gov with TransMolecular as lead sponsor.

NCT NCT00114309
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00114309 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131-I-TM-601 in Adult Patients With Recurrent High-Grade Glioma
Lead sponsor
TransMolecular
Phase
Phase 2
Overall status
Unknown status
Start date
November 30, 2004
Completion date
August 31, 2009
Enrollment
66 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic astrocytoma, gbm, glioblastoma multiforme, gliosarcoma, malignant glioma, oligo-astrocytoma